NCT05168904 2024-02-08
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Suspended
Clinical Trials
11 trialsNCT04996030 2024-01-23
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Syros Pharmaceuticals
Phase 1 Suspended
NCT03659669 2023-10-23
REVEAL
AbbVie
Suspended
NCT04485052 2023-10-23
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Suspended
NCT03229876 2023-07-24
Safety and Efficacy Evaluation of CD19-UCART
Bioray Laboratories
Phase NA Suspended
NCT01982175 2022-06-21
CLL004
Shanghai Zhangjiang Biotechnology Limited Company
Phase 2 Suspended
NCT03722186 2021-03-22
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Suspended
NCT02462265 2018-04-18
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Oshadi Drug Administration
Phase 2 Suspended
NCT01211691 2015-11-17
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Humanigen, Inc.
Phase 1/2 Suspended
NCT01010373 2015-02-10
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
BioMAS Ltd
Phase 2 Suspended
NCT00077493 2007-12-28
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Suspended